Skip to main content

Advertisement

SpringerLink
Log in

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity

  • Review Article
  • Published:
Archives of Toxicology Aims and scope Submit manuscript

Abstract

Lung cancers with an epidermal growth factor receptor (EGFR) gene mutation account for ~40 % of adenocarcinomas in East Asians and ~15 % of those in Caucasians and African Americans, which makes them one of the most common molecularly defined lung cancer subsets. The discriminative clinical and pathological features of lung cancers with EGFR mutations have been intensively studied, and the predictive role of an EGFR mutation for treatment with EGFR tyrosine kinase inhibitors (EGFR-TKIs) is well established. However, controversial issues remain regarding the clinical and therapeutic implications of EGFR mutations in lung cancers. These include the prognostic impact of the EGFR mutation, its predictive implication for successful treatment with anticancer agents other than EGFR-TKIs, appropriate cytotoxic agents for lung cancers with this mutation, and the chemosensitivity of EGFR-mutation-positive lung cancers after acquisition of resistance to EGFR-TKIs. In this review, we discuss these unanswered but important questions, referring to in vitro studies, basic research, retrospective analyses, and the results of phase III clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Arcila ME, Oxnard GR, Nafa K et al (2011) Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 17(5):1169–1180

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bean J, Brennan C, Shih JY et al (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104(52):20932–20937

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ceppi P, Volante M, Novello S et al (2006a) ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17(12):1818–1825

    Article  CAS  PubMed  Google Scholar 

  • Ceppi P, Volante M, Saviozzi S et al (2006b) Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107(7):1589–1596

    Article  CAS  PubMed  Google Scholar 

  • Chen Z, Liu X, Zhao J, Yang H, Teng X (2014) Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma. Int J Clin Exp Pathol 7(11):8039–8045

    PubMed Central  PubMed  Google Scholar 

  • Christoph DC, Asuncion BR, Hassan B et al (2013) Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed. J Thorac Oncol 8(1):19–30

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Cuyun Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ (2014) A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res 6:437–449

    Article  PubMed Central  PubMed  Google Scholar 

  • D’Angelo SP, Janjigian YY, Ahye N et al (2012) Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol 7(12):1815–1822

    Article  PubMed  CAS  Google Scholar 

  • Dong X, Zhao X, Hao Y, Wei Y, Yin Q, Du J (2013) Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status. Clin Lung Cancer 14(6):680–687

    Article  CAS  PubMed  Google Scholar 

  • Engelman JA, Zejnullahu K, Gale CM et al (2007a) PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67(24):11924–11932

    Article  CAS  PubMed  Google Scholar 

  • Engelman JA, Zejnullahu K, Mitsudomi T et al (2007b) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039–1043

    Article  CAS  PubMed  Google Scholar 

  • Ercan D, Xu C, Yanagita M et al (2012) Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2(10):934–947

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Fang S, Wang Z, Guo J et al (2014) Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer. OncoTargets Ther 7:1185–1193

    Google Scholar 

  • Filipits M, Pirker R (2011) Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung cancer. 74(3):355–363

    Article  PubMed  Google Scholar 

  • Friboulet L, Olaussen KA, Pignon JP et al (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368(12):1101–1110

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Fukuoka M, Wu YL, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29(21):2866–2874

    Article  CAS  PubMed  Google Scholar 

  • Gandara DR, Grimminger P, Mack PC et al (2010) Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol 5(12):1933–1938

    Article  PubMed  Google Scholar 

  • Giovannetti E, Mey V, Nannizzi S et al (2005) Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68(1):110–118

    CAS  PubMed  Google Scholar 

  • Han JY, Park K, Kim SW et al (2012) First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 30(10):1122–1128

    Article  CAS  PubMed  Google Scholar 

  • Hotta K, Kiura K, Toyooka S et al (2007) Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2(7):632–637

    Article  PubMed  Google Scholar 

  • Hu H, Pan Y, Li Y et al (2014) Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. OncoTargets Ther 7:1423–1437

    Article  CAS  Google Scholar 

  • Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5(5):341–354

    Article  CAS  PubMed  Google Scholar 

  • Inoue A, Kobayashi K, Maemondo M et al (2013) Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 24(1):54–59

    Article  CAS  PubMed  Google Scholar 

  • Izar B, Sequist L, Lee M et al (2013) The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers. Ann Thorac Surg 96(3):962–968

    Article  PubMed  Google Scholar 

  • Janjigian YY, Park BJ, Zakowski MF et al (2011) Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol 6(3):569–575

    Article  PubMed Central  PubMed  Google Scholar 

  • Jie L, Li XY, Zhao YQ et al (2014) Genotype-phenotype correlation in Chinese patients with pulmonary mixed type adenocarcinoma: relationship between histologic subtypes, TITF-1/SP-a expressions and EGFR mutations. Pathol Res Pract 210(3):176–181

    Article  CAS  Google Scholar 

  • Kalikaki A, Koutsopoulos A, Hatzidaki D et al (2010) Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 69(1):110–115

    Article  PubMed  Google Scholar 

  • Kelly K, Crowley J, Bunn PA Jr et al (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19(13):3210–3218

    CAS  PubMed  Google Scholar 

  • Kim YH, Hirabayashi M, Togashi Y et al (2012) Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902. Cancer Chemother Pharmacol 70(2):271–276

    Article  CAS  PubMed  Google Scholar 

  • Kim YT, Seong YW, Jung YJ et al (2013) The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. J Thorac Oncol 8(2):171–178

    Article  CAS  PubMed  Google Scholar 

  • Kobayashi S, Boggon TJ, Dayaram T et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786–792

    Article  CAS  PubMed  Google Scholar 

  • Kobayashi N, Toyooka S, Ichimura K et al (2008) Non-BAC component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung. J Thorac Oncol 3(7):704–710

    Article  PubMed  Google Scholar 

  • Kosaka T, Yatabe Y, Onozato R, Kuwano H, Mitsudomi T (2009) Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. J Thorac Oncol 4(1):22–29

    Article  PubMed  Google Scholar 

  • Li D, Ambrogio L, Shimamura T et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34):4702–4711

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Li H, Xie L, Lai RS (2013) Association of EGFR mutations with low BRCA1 gene expression in non-small cell lung cancer. Mol Clin Oncol 1(1):195–199

    PubMed Central  PubMed  Google Scholar 

  • Lim KH, Huang MJ, Liu HC, Kuo HT, Tzen CY, Hsieh RK (2007) Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer. Med Oncol 24(4):388–393

    Article  PubMed  Google Scholar 

  • Lin MW, Wu CT, Shih JY, Chang YL, Yang PC (2014) Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas </=2 cm in maximal dimension. J Surg Oncol 110(2):99–106

    Article  CAS  PubMed  Google Scholar 

  • Liu HP, Isaac Wu HD, Chang JW et al (2010) Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan. J Thorac Oncol 5(8):1175–1184

    Article  PubMed  Google Scholar 

  • Liu WS, Zhao LJ, Pang QS, Yuan ZY, Li B, Wang P (2014) Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas. Med Oncol 31(1):771

    Article  PubMed  CAS  Google Scholar 

  • Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139

    Article  CAS  PubMed  Google Scholar 

  • Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–2388

    Article  CAS  PubMed  Google Scholar 

  • Mariano C, Bosdet I, Karsan A et al (2014) A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease. Lung Cancer 83(1):73–77

    Article  PubMed  Google Scholar 

  • Marks JL, Broderick S, Zhou Q et al (2008) Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 3(2):111–116

    Article  PubMed  Google Scholar 

  • Mitsudomi T, Yatabe Y (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98(12):1817–1824

    Article  CAS  PubMed  Google Scholar 

  • Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128

    Article  CAS  PubMed  Google Scholar 

  • Mizuuchi H, Suda K, Sato K, et al (2015) Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib. PloS One 10(4):e0123901

    Article  PubMed Central  PubMed  Google Scholar 

  • Mochinaga K, Tsuchiya T, Nagasaki T et al (2014) High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non–small-cell lung cancer using 5-fluorouracil. Clinical Lung Cancer 15(2):136–144

    Article  CAS  PubMed  Google Scholar 

  • Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957

    Article  CAS  PubMed  Google Scholar 

  • Nakamura, H, Saji, H, Shinmyo, T, et al. (2014) Association of IASLC/ATS/ERS histologic subtypes of lung adenocarcinoma with epidermal growth factor receptor mutations in 320 resected cases. Clin Lung Cancer 16(3):209–15

    Article  PubMed  CAS  Google Scholar 

  • Ohashi K, Sequist LV, Arcila ME et al (2012) Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA 109(31):E2127–E2133

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ohe Y, Ohashi Y, Kubota K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-Arm Cooperative Study in Japan. Ann Oncol 18(2):317–323

    Article  CAS  PubMed  Google Scholar 

  • Okuda K, Sasaki H, Dumontet C et al (2008) Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 62(1):105–112

    Article  PubMed  Google Scholar 

  • Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10):983–991

    Article  CAS  PubMed  Google Scholar 

  • Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–1500

    Article  CAS  PubMed  Google Scholar 

  • Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(36):13306–13311

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  • Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC (2012) The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev 9(3):144–155

    CAS  Google Scholar 

  • Ren S, Chen X, Kuang P et al (2012) Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Cancer 118(22):5588–5594

    Article  CAS  PubMed  Google Scholar 

  • Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246

    Article  CAS  PubMed  Google Scholar 

  • Scagliotti GV, De Marinis F, Rinaldi M et al (2002) Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20(21):4285–4291

    Article  CAS  PubMed  Google Scholar 

  • Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21):3543–3551

    Article  CAS  PubMed  Google Scholar 

  • Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92–98

    Article  CAS  PubMed  Google Scholar 

  • Schmid-Bindert G, Wang Y, Jiang H et al (2013) EBUS-TBNA provides highest RNA yield for multiple biomarker testing from routinely obtained small biopsies in non-small cell lung cancer patients—a comparative study of three different minimal invasive sampling methods. PLoS One 8(10):e77948

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Sequist LV, Waltman BA, Dias-Santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science translational medicine. 3(75):75ra26

    Article  PubMed Central  PubMed  Google Scholar 

  • Sequist LV, Yang JC, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27):3327–3334

    Article  CAS  PubMed  Google Scholar 

  • Shien K, Toyooka S, Yamamoto H et al (2013) Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res 73(10):3051–3061

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Shim HS, Lee da H, Park EJ, Kim SH (2011) Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Med 135(10):1329–1334

    Article  PubMed  Google Scholar 

  • Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y (2013) Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients. Medical oncology. 30(3):645

    Article  PubMed  CAS  Google Scholar 

  • Sonobe M, Nakagawa M, Takenaka K et al (2007) Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. J Surg Oncol 95(1):63–69

    Article  CAS  PubMed  Google Scholar 

  • Su KY, Chen HY, Li KC et al (2012) Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 30(4):433–440

    Article  CAS  PubMed  Google Scholar 

  • Suda K, Mitsudomi T (2013) PTEN—a molecule that cancers abuse to overcome their achilles heels. In: Ke Xu (ed) PTEN structure, mechanisms-of-action, role in cell signaling and regulation, 1st edn. Nova Science Publishers, New York, p 17

    Google Scholar 

  • Suda K, Mitsudomi T (2014) Successes and limitations of targeted cancer therapy in lung cancer. Prog Tumor Res 41:62–77

    Article  PubMed  Google Scholar 

  • Suda K, Mitsudomi T (2015) Racial differences in lung cancer genetics. J Thorac Oncol 10(2):230–231

    Article  PubMed  Google Scholar 

  • Suda K, Onozato R, Yatabe Y, Mitsudomi T (2009) EGFR T790M mutation: a double role in lung cancer cell survival? J Thorac Oncol 4(1):1–4

    Article  PubMed  Google Scholar 

  • Suda K, Murakami I, Katayama T et al (2010) Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 16(22):5489–5498

    Article  CAS  PubMed  Google Scholar 

  • Suda K, Tomizawa K, Fujii M et al (2011) Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 6(7):1152–1161

    Article  PubMed  Google Scholar 

  • Suda K, Mizuuchi H, Maehara Y, Mitsudomi T (2012a) Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny. Cancer Metastasis Rev 31(3–4):807–814

    Article  CAS  PubMed  Google Scholar 

  • Suda K, Tomizawa K, Mizuuchi H et al (2012b) Genetic and prognostic differences of non-small cell lung cancer between elderly patients and younger counterparts. Aging Dis 3(6):438–443

    PubMed Central  PubMed  Google Scholar 

  • Suda K, Sato K, Shimizu S et al (2014) Prognostic implication of predominant histologic subtypes of lymph node metastases in surgically resected lung adenocarcinoma. BioMed Res Int 2014:645681

    Article  PubMed Central  PubMed  Google Scholar 

  • Suehisa H, Toyooka S, Hotta K et al (2007) Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. J Clin Oncol 25(25):3952–3957

    Article  CAS  PubMed  Google Scholar 

  • Sun PL, Seol H, Lee HJ et al (2012) High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 7(2):323–330

    Article  CAS  PubMed  Google Scholar 

  • Sun Y, Yu X, Shi X, Hong W, Zhao J, Shi L (2014) Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients. World J Surg Oncol 12:148

    Article  PubMed Central  PubMed  Google Scholar 

  • Tabara K, Kanda R, Sonoda K et al (2012) Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PLoS One 7(7):e41017

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Takano T, Fukui T, Ohe Y et al (2008) EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 26(34):5589–5595

    Article  CAS  PubMed  Google Scholar 

  • Takezawa K, Pirazzoli V, Arcila ME et al (2012) HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site egfrt790M mutation. Cancer Discov 2(10):922–933

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Tseng JS, Yang TY, Chen KC et al (2014) Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaive patients with EGFR-mutant lung adenocarcinoma. OncoTargets Ther 7:799–805

    Article  CAS  Google Scholar 

  • Turke AB, Zejnullahu K, Wu YL et al (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17(1):77–88

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Vilmar AC, Sorensen JB (2011) Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives. Eur Respir Rev 20(119):45–52

    Article  CAS  PubMed  Google Scholar 

  • Weinstein IB (2002) Cancer. Addiction to oncogenes–the Achilles heal of cancer. Science. 297(5578):63–64

    Article  CAS  PubMed  Google Scholar 

  • Wu SG, Yang CH, Yu CJ et al (2011) Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer 72(3):333–339

    Article  PubMed  Google Scholar 

  • Wu YL, Liam CK, Zhou C, Wu G (2013) First-line erlotinib versus cisplatin/gemcitabine (GP) in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC): Interim analyses from the phase i, open-label, ENSURE study. J Thorac Oncol 8(Suppl. 2):s603 WCLC abstracts

    Google Scholar 

  • Wu YL, Zhou C, Hu CP et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15(2):213–222

    Article  CAS  PubMed  Google Scholar 

  • Xu CW, Wang G, Wang WL et al (2015) Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer. Exp Ther Med 9(3):880–884

    CAS  PubMed Central  PubMed  Google Scholar 

  • Yamashita F, Azuma K, Yoshida T et al (2013) Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy. PLoS One 8(8):e71356

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G (2014) The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. Ann Thorac Surg 98(2):453–458

    Article  PubMed  Google Scholar 

  • Yang JC-H, Schuler MH, Yamamoto N et al (2012) LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 30(suppl):7500 abstr LBA7500

    Google Scholar 

  • Yang JC, Wu YL, Schuler M et al (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16(2):141–151

    Article  CAS  PubMed  Google Scholar 

  • Yano S, Wang W, Li Q et al (2008) Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68(22):9479–9487

    Article  CAS  PubMed  Google Scholar 

  • Yoshizawa A, Sumiyoshi S, Sonobe M et al (2013) Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 8(1):52–61

    Article  CAS  PubMed  Google Scholar 

  • Yu HA, Arcila ME, Rekhtman N et al (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19(8):2240–2247

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Zhang Z, Lee JC, Lin L et al (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44(8):852–860

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735–742

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Current research in my laboratory is supported by Grants-in-Aid of Cancer Research from the Ministry of Education, Science, Sports, and Culture of Japan (K. Suda, 15K18450), grants from the Japan Surgical Society (JSS) Young Researcher Award 2014 (K. Suda), the Kaibara Morikazu Medical Science Promotion Foundation (K. Suda), the Uehara Memorial Foundation (T. Mitsudomi), and the Takeda Science Foundation (T. Mitsudomi).

Conflict of interest

T. Mitsudomi has received honoraria from AstraZeneca, Chugai, Boehlinger-Ingelheim, Pfizer, Roche, Novartis, and Taiho and has played an advisory role for AstraZeneca, Chugai, Boehlinger-Ingelheim, Pfizer, Roche, and Clovis Oncology. K. Suda declares no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511, Japan

    Kenichi Suda & Tetsuya Mitsudomi

Authors
  1. Kenichi Suda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tetsuya Mitsudomi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenichi Suda.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suda, K., Mitsudomi, T. Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. Arch Toxicol 89, 1227–1240 (2015). https://doi.org/10.1007/s00204-015-1524-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00204-015-1524-7

Keywords

Search

Navigation